KYTX
Kyverna Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Kyverna Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
No thesis.
Kyverna Therapeutics, Inc.
5.65
−0.20 · −3.46%
post 5.65 0.00%
Largest filed tie
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | GordonMD Global InvestmentsGordonMD Global | $37.8M | 11.20% | 0.00% | |
| 2 | Gilead SciencesGilead Sciences | $36.8M | 10.88% | 0.00% | |
| 3 | BlackRockBlackRockindex-like | $27.9M | 8.27% | +257.41% | |
| 4 | Bain Capital Life Sciences InvestorsBain Capital Life Sciences Investors | $25.7M | 7.61% | −7.23% | |
| 5 | AIGH Capital ManagementAIGH | $24.9M | 7.37% | +39.79% | |
| 6 | Deerfield ManagementDeerfield | $17.8M | 5.27% | 0.00% | |
| 7 | Vanguard Capital ManagementVanguardindex-like | $16.9M | 5.00% | +6.40% | |
| 8 | T. Rowe Price AssociatesT. Rowe Price | $10.6M | 3.13% | −23.74% | |
| 9 | Geode Capital ManagementGeodeindex-like | $9.4M | 2.77% | +147.61% | |
| 10 | Insight Holdings GroupInsight | $8.8M | 2.61% | 0.00% | |
| 11 | Morgan StanleyMorgan Stanley | $8.8M | 2.59% | +0.51% | |
| 12 | State StreetState Streetindex-like | $8.8M | 2.59% | +610.22% | |
| 13 | Propel Bio ManagementPropel Bio | $7.9M | 2.33% | +37.05% | |
| 14 | Woodline PartnersWoodline Partners | $7.5M | 2.23% | 0.00% | |
| 15 | Millennium ManagementMillennium | $5.7M | 1.69% | −36.37% | |
| 16 | MBB Public Markets IMBB Public Markets I | $5.5M | 1.62% | 0.00% | |
| 17 | Adage Capital Partners GPAdage Capital Partners GP | $4.5M | 1.32% | 0.00% | |
| 18 | D. E. ShawD. E. Shaw | $4.2M | 1.24% | −34.96% | |
| 19 | Wells FargoWells Fargo | $3.3M | 0.98% | +226.06% | |
| 20 | UBS GroupUBS | $3.3M | 0.96% | −18.72% | |
| 21 | Goldman Sachs GroupGoldman Sachs | $3.0M | 0.88% | +57.45% | |
| 22 | Renaissance TechnologiesRenaissance Technologies | $3.0M | 0.88% | −9.14% | |
| 23 | Citadel AdvisorsCitadel | $2.9M | 0.85% | +267.39% | |
| 24 | Charles Schwab Investment ManagementCharles Schwabindex-like | $2.8M | 0.84% | +51.44% | |
| 25 | Northern TrustNorthern Trustindex-like | $2.8M | 0.83% | +304.08% |
120 managers report $337.8M of Kyverna Therapeutics on form 13F for the quarter ended Jun 30 '26. 19 of them hold 80% of it; GordonMD Global is largest at 11.20%.
Expected move
Inputsspot 5.67exp Nov 20ATM strike 5ATM straddle 1.60IV 147%